Cargando…
Development of polyclonal heavy chain antibodies targeting programmed death ligand-1
Programmed death ligand-1 (PD-L1, CD274 and B7-H1) has been described as a ligand for immune inhibitory receptor programmed death protein 1 (PD-1). With binding to PD-1 on activated T cells, PD-L1 can prevent T cell responses via motivating apoptosis. Consequently, it causes cancers immune evasion a...
Autores principales: | Oghalaie, Akbar, Shoari, Alireza, Kazemi-Lomedasht, Fatemeh, Rahimi-Jamnani, Fatemeh, Mahboudi, Fereidoun, Ghaderi, Hajarossadat, Hosseininejad-Chafi, Mohammad, Moazzami, Reza, Ashja Ardalan, Arghavan, Piri-Gavgani, Somayeh, Shahbazzadeh, Delavar, Behdani, Mahdi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Urmia University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298837/ https://www.ncbi.nlm.nih.gov/pubmed/37383651 http://dx.doi.org/10.30466/vrf.2022.553274.3461 |
Ejemplares similares
-
Development and characterization of single domain monoclonal antibody against programmed cell death ligand-1; as a cancer inhibitor candidate
por: Oghalaie, Akbar, et al.
Publicado: (2022) -
Tumor Suppression by PD-1/PD-L1 Interaction Blockage in Mice Model
por: Salehi, Shima, et al.
Publicado: (2023) -
In vivo solid tumor targeting with recombinant VEGF-diphtheria immunotoxin
por: Hosseininejad-Chafi, Mohammad, et al.
Publicado: (2022) -
Antiadhesive and cytotoxic effect of Iranian Vipera lebetina snake venom on lung epithelial cancer cells
por: Oghalaie, Akbar, et al.
Publicado: (2017) -
Development of camelid monoclonal nanobody against SLC39A6 zinc transporter protein
por: Ghaderi, Hajarossadat, et al.
Publicado: (2021)